Minerva Neurosciences financials
$3.35−1.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$10.6M | -$16.7M | -$5.0M | -$2.8M | -$3.4M | -$3.9M | -$4.5M | -$4.4M | -$6.3M | -$6.7M | -$7.2M | -$6.1M |
| Net income | $16.6M | -$125.4M | -$283.7M | -$2.7M | -$3.3M | -$3.8M | -$4.3M | $22.5M | -$8.2M | -$8.6M | -$9.0M | -$7.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.14 | $-2.86 | $-25.45 | $-0.36 | $-0.43 | $-0.50 | $-0.56 | $2.97 | $-1.09 | $-1.13 | $-1.19 | $-1.03 |
| EBITDA | -$10.6M | -$16.7M | -$5.0M | -$2.8M | -$3.4M | -$3.9M | -$4.5M | -$4.4M | -$6.3M | -$6.7M | -$7.2M | -$6.1M |
| Operating cash flow | -$13.3M | -$5.4M | -$4.5M | -$2.9M | -$2.0M | -$4.1M | -$5.2M | -$4.4M | -$3.9M | -$6.1M | -$6.0M | -$4.8M |
| Free cash flow | -$13.3M | -$5.4M | -$4.5M | -$2.9M | -$2.0M | -$4.1M | -$5.2M | -$4.4M | -$3.9M | -$6.1M | -$6.0M | -$4.8M |
| Diluted shares | 79.1M | 43.9M | 11.1M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M | 7.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.7M | $32.7M | $82.3M | $12.3M | $15.2M | $17.3M |
| Short-term investments | $50.6M | $45.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $95.1M | $94.0M | $98.0M | $28.1M | $30.4M | $32.8M |
| Total liabilities | $296.6M | $343.1M | $233.8M | $62.7M | $62.5M | $61.9M |
| Shareholders' equity | -$213.3M | -$254.0M | -$140.7M | -$34.6M | -$32.1M | -$29.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology